Midatech Pharma PLC Posting of Annual Report & Notice of AGM (6142M)
May 24 2022 - 6:09AM
UK Regulatory
TIDMMTPH
RNS Number : 6142M
Midatech Pharma PLC
24 May 2022
24 May 2022
Midatech Pharma PLC
("Midatech" or the "Company")
Posting of Annual Report & Notice of AGM
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
bio-distribution of medicines, announces that its Notice of Annual
General Meeting ("AGM") was posted to shareholders yesterday, along
with the Annual Report for the year ended 31 December 2021. The
documents are also available in the "Investors" section of the
Company's website at
www.midatechpharma.com/financial-reports-accounts .
While the Company will hold the 2022 AGM at its offices at
2.00pm at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ on 20 June
2022, shareholders may not wish to attend the AGM in person but
instead be represented by the Chair of the AGM acting as their
proxy. Shareholders may participate, but not vote, in the AGM via
Zoom by contacting Sara Siddall at sara.siddall@midatechpharma.com
who will provide details on how to join the Zoom call. Further
details on how to vote by proxy are set out in the Notice of
AGM.
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com
Strand Hanson Limited (Nominated and Financial Adviser)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
Turner Pope Investments (TPI) Limited (Broker)
Andrew Thacker / James Pope (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is an R&D company focused on 'Making Medicines Better'
by improving delivery of drugs in the body. The Company combines
existing medications with its proprietary and innovative drug
delivery technologies to provide compelling oncology and rare
disease products that have the potential to powerfully impact
the lives of patients undergoing treatment for life threatening
diseases.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading edge nanotechnology
used for targeting medications to sites of disease.
By improving bio-delivery and biodistribution of approved
existing molecules, Midatech's unique R&D has the potential
to make medicines better, lower technical risks, accelerate
regulatory approval and route to market, and provide newly
patentable products. The platform nature of the technologies
allows the potential to develop multiple drug assets rather
than being reliant on a limited number of programmes.
Midatech's technologies are supported by 36 patent families
including 120 granted patents and an additional 70 patent
applications.
Midatech's headquarters and R&D facility is in Cardiff, UK.
For more information please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAEAESLAEPAEFA
(END) Dow Jones Newswires
May 24, 2022 06:09 ET (10:09 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024